Telix Pharmaceuticals (TLX) Other Non-Current Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 60.95% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, down 60.95% year-over-year, with the annual reading at $3.5 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $3.5 million at Telix Pharmaceuticals, down from $9.0 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $9.0 million in Q4 2024, with the low at $3.5 million in Q4 2025.
  • Average Other Non-Current Liabilities over 3 years is $5.9 million, with a median of $5.2 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities soared 72.85% in 2024, then crashed 60.95% in 2025.
  • Over 3 years, Other Non-Current Liabilities stood at $5.2 million in 2023, then skyrocketed by 72.85% to $9.0 million in 2024, then plummeted by 60.95% to $3.5 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $3.5 million, $9.0 million, and $5.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.